Benjamin Patton’s Post

Finding out which breast cancer cell line expresses more estrogen receptors is crucial for research and treatment planning. With Bionl.ai's General Search, you get the answer quickly and accurately. Our feature delivers fast insights and relevant resources, helping you stay informed and make data-driven decisions. Try it today and streamline your research: https://www.bionl.ai #Bionlai | #LiteratureSearch | #Bioinformatics | #BreastCancer | #Genomics | #NoCodePlatform | #Pharmacogenomics | #CancerResearch | #CellLine | #EstrogenReceptor

Friday, April 12th, the #𝐅𝐃𝐀’𝐬 𝐎𝐧𝐜𝐨𝐥𝐨𝐠𝐢𝐜 𝐃𝐫𝐮𝐠𝐬 𝐀𝐝𝐯𝐢𝐬𝐨𝐫𝐲 𝐂𝐨𝐦𝐦𝐢𝐭𝐭𝐞𝐞 𝐯𝐨𝐭𝐞𝐝 𝟏𝟐 𝐭𝐨 𝟎 𝐭𝐡𝐚𝐭 𝐭𝐡𝐞 𝐭𝐨𝐭𝐚𝐥𝐢𝐭𝐲 𝐨𝐟 𝐚𝐯𝐚𝐢𝐥𝐚𝐛𝐥𝐞 𝐝𝐚𝐭𝐚 𝐬𝐮𝐩𝐩𝐨𝐫𝐭𝐬 𝐭𝐡𝐞 𝐮𝐬𝐞 𝐨𝐟 𝐦𝐢𝐧𝐢𝐦𝐚𝐥 𝐫𝐞𝐬𝐢𝐝𝐮𝐚𝐥 𝐝𝐢𝐬𝐞𝐚𝐬𝐞 (#𝐌𝐑𝐃) 𝐚𝐬 𝐚𝐧 𝐞𝐧𝐝 𝐩𝐨𝐢𝐧𝐭 𝐟𝐨𝐫 𝐚𝐜𝐜𝐞𝐥𝐞𝐫𝐚𝐭𝐞𝐝 𝐚𝐩𝐩𝐫𝐨𝐯𝐚𝐥 𝐨𝐟 𝐧𝐞𝐰 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭𝐬 𝐟𝐨𝐫 𝐩𝐚𝐭𝐢𝐞𝐧𝐭𝐬 𝐰𝐢𝐭𝐡 𝐦𝐮𝐥𝐭𝐢𝐩𝐥𝐞 #𝐦𝐲𝐞𝐥𝐨𝐦𝐚. Sebia’s CEO, Jean Marc Chermette touts, “This is a tremendous advance for patients with multiple myeloma, enabling investigators and biopharma companies to get much needed new promising agents made available and accessible. MRD plays a major role in the care of myeloma patients and having an analytically validated blood-based MRD assay such as M-inSight will serve a crucial need and spare having to perform for bone marrow biopsies”. #Sebia congratulates Representatives from The University of Miami’s Sylvester Comprehensive Cancer Center and the i2TEAMM who presented three independent data sets from a meta-analysis based on patient-level data from several clinical trials. The level of rigor of these analyses are superb and sets a new standard for biomarker development in oncology. ➡️ Visit https://lnkd.in/eXd5eNkT to learn more about M-inSight! #Minimalresidualdisease #Multiplemyeloma #MinSight

Cancer is a fibrotic disease—and last year the FDA issued a Letter of Support for the inclusion of our nordicPRO-C3™ biomarker in tumor fibrosis studies. Active tumor fibrosis is the leading factor in cold, dense, hypoxic, and collagen-rich tumors. Watch Nicholas Willumsen, Director of Oncology at Nordic Bioscience, discuss how the FDA's endorsement may impact clinical decision-making and patient outcomes. PRO-C3 is measured on the Roche Diagnostics cobas® e automated platform, increasing robustness and accuracy in sample measurements and enabling future in-vitro diagnostic (IVD) use. Morten Asser Karsdal Neel Ingemann Nissen Claus S. von Arenstorff Daniel Gabor #FDA #DrugDevelopment #TumorFibrosis #CancerReserach #ClinicalTrials

🔥 Have burning questions for the curators behind COSMIC Actionability? Here's your chance to get answers!   Join us on March 7 for an exclusive webinar featuring a live Q&A session with Dr. Steve Jupe, COSMIC Actionability's principal curator. Led by Dr. Kyle Nilson, this webinar will explore a series of use cases demonstrating how #cancer and #biopharma labs can harness COSMIC (Catalogue of Somatic Mutations in Cancer) to: ☑️ Evaluate genomic loci using COSMIC’s comprehensive coding and non-coding variant annotations ☑️ Integrate variants with curated findings and summaries of mutational impact and clinical actionability ☑️ Use mutational signatures for potential clinical diagnosis and drug development applications   Don't miss out! Register now ⬇️ #drugdevelopment #precisiononcology

Theralase Technologies (TSXV: TLT) CEO Roger DuMoulin-White joined Steve Darling from Proactive to share details of an update on the company's Phase II Non-Muscle Invasive #BladderCancer clinical study during an interview with Steve Darling from Proactive. DuMoulin-White shared the significant findings from the study, revealing that it has provided the primary study treatment to 63 patients. The interim clinical data from Study II shows promising results, with a Complete Response (CR) rate of 54% at 6 months, 38% at 12 months, and 37% at 15 months. These CR rates surpass the guidelines set by the International Bladder Cancer Group (IBCG). Additionally, at the 90 Day Assessment Visit, 56% of Evaluable Patients achieved a CR, and 63% achieved a Total Response (CR + IR). At 450 days, 37% achieved a CR, and 41% achieved a TR. Watch at #Proactive #ProactiveInvestors #TSXV #OTCQB #TLT #TLTFF http://ow.ly/YLin10598yw

Oncologists recently gathered at #ASCO2024 to discuss the latest in cancer research, with a major focus on biomarkers and antibody-drug conjugates (ADCs). Highlights included groundbreaking trial data for small molecules like Lorbrena and Tagrisso, emphasizing the effectiveness of targeted biomarker therapies. Notable advancements in biomarker technologies and individualized neoantigen therapies were also showcased, alongside challenges in ADC efficacy and safety. Future discussions will explore new biomarker detection methods and multitarget ADCs to enhance specificity and reduce side effects. To read the full CRA Insights by Aaron E., click here: https://crai.news/a88 #CRALifeSciences

Pharmacogenomics propels cancer treatment into a personalized era. Harnessing the power of genetics, tailored therapies promise improved outcomes. Despite challenges, breakthroughs inspire hope, steering us towards more effective and precise cancer treatments. Beyond oncology, pharmacogenomics fuels the rise of precision medicine, offering personalized healthcare and a brighter future for cancer patients worldwide. #sentropharma #pharmaceuticalindustry #pharmaceuticalsupplies #pharmaceuticaldistributor #Pharmacogenomics #PrecisionMedicine #CancerResearch #personalisedtreatmet #cancertreatment #Genomeceutical #pharmaresearch

🌟𝗣𝗮𝗻𝗶𝘁𝘂𝗺𝘂𝗺𝗮𝗯: 𝗔 𝗣𝗼𝘄𝗲𝗿𝗳𝘂𝗹 𝗔𝗹𝗹𝘆 𝗶𝗻 𝗖𝗮𝗻𝗰𝗲𝗿 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵🧬   Panitumumab from the original Vectibix® can provide invaluable insights into colorectal cancer research. By targeting 🎯 and inhibiting ❌ the epidermal growth factor receptor (EGFR) pathway, this molecule offers a powerful tool 🛠️ for understanding disease mechanisms and developing innovative therapies 💡.   Visit our online shop 🛒 today to access this essential research compound 🔬 and explore our batch library 📚 with other top-quality clinical-grade molecules from original therapeutics. Evidentic offers global access 🌍, reliable sourcing 🔗, and research benefits 📈. Don't miss the opportunity to advance your cancer research! 🧬   #Panitumumab #Vectibix #ColorectalCancer #CancerResearch #EGFR #TargetedTherapy #ClinicalResearch #Biotechnology #Evidentic #GlobalAccess #InnovativeTherapies #MolecularResearch #Oncology #ResearchCompounds

Unlocking the Secrets of Cancer Metabolism: Dive into the latest brochure exploring the power of Seahorse Real-Time Cell Metabolic Analysis in cancer research and therapeutic development. Discover how this cutting-edge technology can illuminate metabolic vulnerabilities and drive advancements in cancer drug development. Explore the applications of a real-time metabolic analysis platform for cancer research and cell therapeutics development. Contact us now at marketing@medispec.in or 77188 10037 to learn more! #medispec #cellmetabolism #seahorse #cancerresearch #cellanalysis #drugdevelopment